Supportive Care for Lung Cancer: 142 Real Stories

142 stories match lung cancer and supportive care. 77 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Extensive-stage small-cell lung cancer with immune-related diabetes and stable disease at 2 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor PD-L1 not reported. Immune-related diabetes showed very low C-peptide and negative diabetes autoantibodies; thyroiditis also occurred.

Metastatic Site: pancreas; pleura/pleural effusion; mediastinal lymph…

Two years after the SCLC diagnosis, she was alive with stable oncologic disease after later brain metastases were treated with whole-brain radiotherapy, and she remained insulin-dependent.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small-cell lung cancer with anti-NMDAR encephalitis: neurologic recovery and cancer care ongoing

Patient Info: Anonymized, Male, 70+

Biomarkers: Anti-NMDAR antibodies positive in cerebrospinal fluid; tumor molecular markers not reported

He recovered without significant neurologic sequelae and had no recurrence of neuropsychiatric symptoms; SCLC treatment with carboplatin and paclitaxel began after discharge, and cancer remission status was not documented.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Localized lung adenocarcinoma: lobectomy followed by air-leak repair

Patient Info: Anonymized, Male, 60s

After lobectomy and a second thoracoscopic repair for persistent postoperative air leak, the air leak resolved by postoperative day 3 and had not recurred at 2-month follow-up.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung adenocarcinoma with gelatinous malignant pleural effusion managed with PleurX catheter and hyaluronidase

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: TTF-1-positive; Napsin A-positive; non-small-cell carcinoma consistent with adenocarcinoma; next-generation sequencing pending

Metastatic Site: pleura / malignant pleural effusion

Her Stage IV lung adenocarcinoma symptoms improved through pleural drainage with PleurX catheter and intrapleural hyaluronidase while oncology planned definitive chemoradiation and possible biomarker-guided therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma presenting with central diabetes insipidus

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Weak TTF-1-positive; weak Napsin A-positive; weak p63-positive; CK5/6-negative; molecular testing not performed because of financial constraints

Metastatic Site: brain lesions, cervical spine bone lesions

He died shortly after the second cycle of platinum-based chemotherapy for metastatic lung adenocarcinoma that presented with central diabetes insipidus and brain/bone lesions.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV lung adenocarcinoma with Aspergillus-associated empyema: disease control after chemotherapy and antifungal therapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: Pathogenic NF1 mutation; CEA elevated in pleural fluid; Aspergillus fumigatus cultured from bronchoalveolar lavage fluid

Metastatic Site: pleural disease/effusion (M1a)

After 6 cycles of pemetrexed/cisplatin and 6 months of antifungal therapy for Aspergillus-associated empyema, 12-month follow-up showed disease stability without recurrence.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Recurrent lung adenocarcinoma with bevacizumab-associated glomerular microangiopathy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: No tumor molecular biomarkers reported. Kidney biopsy and complement/immune deposits supported bevacizumab-related kidney microangiopathy.

Metastatic Site: pleura

He was living with recurrent metastatic lung adenocarcinoma after pleural spread and had persistent renal dysfunction and severe proteinuria from bevacizumab-associated glomerular microangiopathy despite stopping bevacizumab.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIB non-squamous NSCLC on chemoimmunotherapy: alcohol-related hypertonic hyponatremia corrected during oncology follow-up

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Tumor biomarkers not reported. Severe hyponatremia workup showed high serum osmolality and ethanol level.

He remained under oncology follow-up for Stage IIIB non-squamous NSCLC while alcohol-related hypertonic hyponatremia improved after detoxification and alcohol cessation.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IVA lung adenosquamous carcinoma: complete response after paclitaxel, nedaplatin, and tislelizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Adenosquamous lung cancer markers; PD-L1 TPS 18%; KRAS, BRAF, PIK3CA, FLT1 mutation; TMB 3.7

Metastatic Site: pleura/chest wall, cervical lymph nodes, axillary…

As of March 30, 2025, he maintained complete response with normal tumor markers, no radiologic evidence of progression or recurrence, and progression-free survival of 46.5 months after paclitaxel/nedaplatin/tislelizumab followed by maintenance tislelizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

EML4-ALK lung cancer: complete remission on alectinib for 4 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EML4-ALK fusion

Metastatic Site: brain

Alectinib produced complete remission for nearly 4 years; after grade 3 colitis/ulcers, she switched to ceritinib and maintained stable tumor control without recurrent intestinal ulcers or colitis.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: managing pembrolizumab-induced myasthenia gravis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Anti-acetylcholine receptor antibody elevated; TSH elevated during immune-related adverse event workup; cancer biomarkers not reported

At 9 months after the immune-related myasthenia gravis presentation, lung cancer remained in complete response while she continued low-dose prednisolone, pyridostigmine, levothyroxine, and nighttime NIV.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Recurrent lung adenocarcinoma: sick sinus syndrome during anlotinib treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: driver genes negative

Recurrent/progressive lung adenocarcinoma was being treated with anlotinib when sick sinus syndrome developed; the patient received a permanent pacemaker and remained alive under follow-up, but post-pacemaker cancer status was not fully reported.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer with paraneoplastic neurological syndrome

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Paraneoplastic antibody panel positive for anti-Hu, anti-AMPH, anti-Ri

Metastatic Site: left axillary lymph nodes

Over 2 years of follow-up, CT showed stable complete response, tumor markers stayed normal, no new metastases appeared, and neurological symptoms did not worsen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IV small cell lung cancer: no abnormality after chemotherapy, radiotherapy, and TCM follow-up

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: bilateral lungs; left supraclavicular lymph nodes;…

After chemotherapy, radiotherapy, supportive care, and longitudinal TCM follow-up, imaging showed disappearance of the main lung, nodal, and intrapulmonary lesions, with no abnormality found after 4 years of follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage 4 lung cancer: complete response to chemoimmunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 20 duplication with PD-L1 TPS 70%; P40/CK5/6 positive squamous markers; Ki-67 60%.

Metastatic Site: right adrenal gland; possible adjacent…

As of May 7, 2024, CT follow-up showed no evidence of disease after chemoimmunotherapy, conversion surgery with pathologic complete response, and pembrolizumab maintenance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage I lung adenocarcinoma: post-lobectomy hemothorax resolved with tPA/DNase

Patient Info: Anonymized, Female, 70+ | Stage I

Early-stage lung adenocarcinoma was surgically treated with left upper lobectomy; postoperative hemothorax resolved after chest-tube drainage, bronchoscopy, and intrapleural tPA/DNase, with no hemothorax recurrence at follow-up.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3C lung cancer: complete remission on immunotherapy and chemotherapy

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: EGFR wild-type; ALK rearrangement not detected; PD-L1 <1%

Complete tumor remission with no recurrence more than 6 months after durvalumab, tremelimumab, carboplatin, and nab-paclitaxel for Stage IIIC driver-negative NSCLC, despite severe immune, infectious, cardiac, renal, and fistula complications that later resolved or stabilized.

PubMed Central
OutcomeCancer-Free / NED
Lindsay, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Lindsay's Patient Story

Patient Info: Lindsay Wagner, Female, 40s | Stage IV

Biomarkers: ALK-positive mutation / ALK rearrangement

Metastatic Site: brain; liver; bone; kidneys; lungs;…

As of September 2024, Lindsay was still on lorlatinib/Lorbrena with her lungs, liver, and kidneys described as stable, while isolated brain/bone areas were treated with radiation and monitored.

The Patient Story
OutcomeResponding Well